Jens Juul Holst

Jens Juul Holst

Professor

ORCID: 0000-0001-6853-3805

Publication year:
All
276 - 300 out of 1,839Page size: 25
Sort by: 1st author
  1. Published

    Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

    Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

    Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes

    Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

    Deacon, Carolyn F. & Holst, Jens Juul, Oct 2013, In: Expert Opinion on Pharmacotherapy. 14, 15, p. 2047-58 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

    Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In: Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

    Deacon, Carolyn F., Carr, R. D. & Holst, Jens Juul, 2008, In: Frontiers in Bioscience. 13, p. 1780-94 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Differential regional metabolism of glucagon in anesthetized pigs.

    Deacon, Carolyn F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M. & Holst, Jens Juul, 2003, In: American Journal of Physiology: Endocrinology and Metabolism. 285, 3, p. E552-60

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

    Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Advances in Therapy. 26, 5, p. 488-99 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

    Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In: American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9

    Research output: Contribution to journal › Journal article › Research › peer-review

  12. Published

    GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

    Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In: American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75

    Research output: Contribution to journal › Journal article › Research › peer-review

  13. Published

    Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

    Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  14. Published

    Immunoassays for the incretin hormones GIP and GLP-1

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  15. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-140 8 p.

    Research output: Contribution to journal › Review › Research › peer-review

  16. Published

    DPP-4 inhibition – advances in our understanding of diabetes management

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: European Endocrinology. 4, p. 47-49

    Research output: Contribution to journal › Review › Research

  17. Published

    In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment

    Decock, A., Verroken, C., Van de Velde, F., Vilsbøll, Tina, Holst, Jens Juul, T’Sjoen, G. & Lapauw, B., 2021, In: Clinical Endocrinology. 95, 1, p. 65-73

    Research output: Contribution to journal › Journal article › Research › peer-review

  18. Published

    Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice

    Degerman, E., Manganiello, V., Holst, Jens Juul & Ahren, B., 2004, In: Eur. J. Pharmacol.. 498, p. 319-323

    Research output: Contribution to journal › Journal article › Research › peer-review

  19. Published

    Liraglutide preserved insulin secretion in adults with newly diagnosed type 1 diabetes: the NewLira trial: [Meeting Abstract}

    Dejgaard, T. F., Frandsen, C., Kielgast, U., Andersen, H. U., Thorsteinsson, B., Krarup, T., Holst, Jens Juul & Madsbad, Sten, 2019, In: Diabetologia. 62, Supl. 1/SI, p. S75-S75 145.

    Research output: Contribution to journal › Conference abstract in journal › Research

  20. Published

    Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

    Dejgaard, T. F., Knop, Filip Krag, Tarnow, L., Frandsen, C. S., Hansen, T. S., Almdal, Thomas Peter, Holst, Jens Juul, Madsbad, Sten & Andersen, H. U., 2015, In: B M J Open. 5, 4, p. 1-8 8 p., e007791.

    Research output: Contribution to journal › Journal article › Research › peer-review

  21. Published

    Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

    Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, Thomas Peter, Urhammer, Søren Asger, Pedersen-Bjergaard, Ulrik, Jensen, T., Jensen, Andreas Kryger, Holst, Jens Juul, Tarnow, L., Knop, Filip Krag, Madsbad, Sten & Andersen, H. U., Mar 2016, In: The Lancet Diabetes & Endocrinology. 4, 3, p. 221–232 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  22. Published

    Liraglutide for treating type 1 diabetes

    Dejgaard, T. F., Frandsen, C. S., Holst, Jens Juul & Madsbad, Sten, Apr 2016, In: Expert Opinion on Biological Therapy. 16, 4, p. 579-90 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  23. Published

    The incretin/glucagon system as a target for pharmacotherapy of obesity

    Del Prato, S., Gallwitz, B., Holst, Jens Juul & Meier, J. J., 2022, In: Obesity Reviews. 23, 2, 13 p., e13372.

    Research output: Contribution to journal › Journal article › Research › peer-review

  24. Published

    Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects

    Demant, M., Bagger, J. I., Suppli, M. P., Lund, A., Gyldenløve, M., Hansen, K. B., Hare, Kristine Juul, Christensen, Mikkel Bring, Sonne, D. P., Holst, Jens Juul, Vilsbøll, Tina & Knop, Filip Krag, Dec 2018, In: Metabolic Syndrome and Related Disorders. 16, 10, p. 530-536 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  25. Published

    Metabolic effects of one-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Demant, Mia Grønlund, Suppli, M. P., Foghsgaard, S., Gether, L., Grøndahl, M. F. G., Dalsgaard, N. B., Bergmann, S. S., Lanng, A. R., Gasbjerg, Lærke Smidt, Thomasen, M., Bagger, J. I., Strandberg, C., Kønig, M. J., Grønbæk, H., Becker, U., Holst, Jens Juul, Knop, J., Gillum, M. P., Vilsbøll, Tina & Knop, Filip Krag, Apr 2021, In: European Journal of Endocrinology. 185, 1, p. 23-32

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...8 9 10 11 12 13 14 15 ...74 Next

ID: 4207